share_log

復星醫藥：海外監管公告 - 關於參與設立的投資基金完成私募投資基金備案的公告

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Jun 25 18:31
Summary by Futu AI
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）宣布其控股子公司/企業參與設立的深圳生物醫藥產業基金已於2024年3月12日完成私募股權投資基金的備案。該基金由深圳復鑫深耀投資合伙企業（有限合伙）、復星醫藥產業發展（深圳）有限公司、上海復健股權投資基金管理有限公司與其他七方投資人共同出資設立。基金管理人為上海復健股權投資基金管理有限公司，托管人為中國建設銀行股份有限公司。復星醫藥董事會保證公告內容真實、準確、完整，並承擔相應法律責任。該基金的設立旨在投資生物醫藥產業，並由復星醫藥的控股子公司擔任基金管理人。此項進展於2024年6月25日由復星醫藥董事會公告。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）宣布其控股子公司/企業參與設立的深圳生物醫藥產業基金已於2024年3月12日完成私募股權投資基金的備案。該基金由深圳復鑫深耀投資合伙企業（有限合伙）、復星醫藥產業發展（深圳）有限公司、上海復健股權投資基金管理有限公司與其他七方投資人共同出資設立。基金管理人為上海復健股權投資基金管理有限公司，托管人為中國建設銀行股份有限公司。復星醫藥董事會保證公告內容真實、準確、完整，並承擔相應法律責任。該基金的設立旨在投資生物醫藥產業，並由復星醫藥的控股子公司擔任基金管理人。此項進展於2024年6月25日由復星醫藥董事會公告。
Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd) announced that a private equity fund established by a holding subsidiary/company participated in the formation of the Shenzhen biomedical industry fund, which completed the filing of private equity investment funds on March 12, 2024. The fund was jointly funded by Shenzhen Foshin Shenyao Investment Partnership Enterprise (Limited Partnership), Fosun Pharmaceutical Industry Development (Shenzhen) Co., Ltd., Shanghai Rehab Equity Investment Fund Management Co., Ltd., and other seven investors. The fund manager is Shanghai Rehab Equity Investment Fund Management Co., Ltd., and the custodian is China Construction Bank Co., Ltd. The board of directors of Fosun Pharma guarantees the truthfulness, accuracy, and completeness of the announcement and bears the corresponding legal responsibility. The establishment of the fund aims to invest in the biomedical industry, and it is managed by a holding subsidiary of Fosun Pharma. This development was announced by the board of directors of Fosun Pharma on June 25, 2024.
Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co., Ltd) announced that a private equity fund established by a holding subsidiary/company participated in the formation of the Shenzhen biomedical industry fund, which completed the filing of private equity investment funds on March 12, 2024. The fund was jointly funded by Shenzhen Foshin Shenyao Investment Partnership Enterprise (Limited Partnership), Fosun Pharmaceutical Industry Development (Shenzhen) Co., Ltd., Shanghai Rehab Equity Investment Fund Management Co., Ltd., and other seven investors. The fund manager is Shanghai Rehab Equity Investment Fund Management Co., Ltd., and the custodian is China Construction Bank Co., Ltd. The board of directors of Fosun Pharma guarantees the truthfulness, accuracy, and completeness of the announcement and bears the corresponding legal responsibility. The establishment of the fund aims to invest in the biomedical industry, and it is managed by a holding subsidiary of Fosun Pharma. This development was announced by the board of directors of Fosun Pharma on June 25, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.